Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioXcel Therapeutics, Inc. (BTAI : NSDQ)

• Company Description    BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. Number of Employees: 80

• Price / Volume Information    Yesterday's Closing Price: $1.60 Daily Weekly Monthly 20 Day Moving Average: 418,987 shares Shares Outstanding: 21.87 (millions) Market Capitalization: $34.99 (millions) Beta: 0.21 52 Week High: $9.26 52 Week Low: $1.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.44% -23.32% 12 Week -42.45% -43.37% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 555 LONG WHARF DRIVE - NEW HAVEN,CT 06511 USA ph: 475-238-6837 fax: - nic.johnson@russopartnersllc.com http://www.bioxceltherapeutics.com

• General Corporate Information    Officers Vimal Mehta - Chief Executive Officer; President; and Director Peter Mueller - Chairman of the Board of Directors Richard Steinhart - Senior Vice President and Chief Financial Officer June Bray - Director Sandeep Laumas - Director Peer Information BioXcel Therapeutics, Inc. (CORR.) BioXcel Therapeutics, Inc. (RSPI) BioXcel Therapeutics, Inc. (CGXP) BioXcel Therapeutics, Inc. (BGEN) BioXcel Therapeutics, Inc. (GTBP) BioXcel Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09075P204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 21.87 Most Recent Split Date: 2.00 (0.06:1) Beta: 0.21 Market Capitalization: $34.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 49.16% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 46.53 EPS Growth vs. Year Ago Period: 57.42% vs. Previous Quarter: 11.02% Sales Growth vs. Year Ago Period: -54.21% vs. Previous Quarter: -18.33% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -185.00 06/30/25 - -134.45 Current Ratio 12/31/25 - - 09/30/25 - 1.17 06/30/25 - 0.76 Quick Ratio 12/31/25 - - 09/30/25 - 1.16 06/30/25 - 0.74 Operating Margin 12/31/25 - - 09/30/25 - -9,070.61 06/30/25 - -5,869.82 Net Margin 12/31/25 - - 09/30/25 - -9,070.61 06/30/25 - -5,869.82 Pre-Tax Margin 12/31/25 - - 09/30/25 - -9,070.61 06/30/25 - -5,869.82 Book Value 12/31/25 - - 09/30/25 - -4.45 06/30/25 - -16.26 Inventory Turnover 12/31/25 - - 09/30/25 - 1.68 06/30/25 - 2.53 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©